Trials / Completed
CompletedNCT01786915
Safety and Pharmacokinetic (PK) Study of Oral Bendavia Administered for 7 Days
Phase 1 Randomized, Double-Blind, Placebo-controlled Study of the Safety, Tolerability and Pharmacokinetics of Repeat Administration (7 Days) of Ascending Oral Doses of Bendavia in Healthy Volunteers
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 30 (actual)
- Sponsor
- Stealth BioTherapeutics Inc. · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to assess the study medication blood levels after administration of a repeat oral capsules (one capsule each day for seven days) of Bendavia at one of two dose levels. The effects of Bendavia on the volunteers will also be assessed.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Bendavia 10mg | |
| DRUG | Bendavia 50mg | |
| DRUG | Placebo |
Timeline
- Start date
- 2013-02-01
- Primary completion
- 2013-03-01
- Completion
- 2013-03-01
- First posted
- 2013-02-08
- Last updated
- 2014-04-02
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01786915. Inclusion in this directory is not an endorsement.